plat

(redirected from Reteplase)
Also found in: Dictionary, Thesaurus, Medical, Legal, Financial, Wikipedia.
Related to Reteplase: Tenecteplase

plat

[plat]
(mapping)
A plan that shows land ownership, boundaries, and subdivisions together with data for description and identification of various parts.

plat

A map, plan, or chart of a city, town, section, or subdivision, indicating the location and boundaries of individual properties.
References in periodicals archive ?
Patients were randomized for thrombolytic therapy with streptokinase (Behring; 1.5 million U intravenous [IV] within 1 h) or reteplase (MIRel, Reliance Life Sciences Pvt.
Reteplase was first studied in a primate model of intracranial thrombosis [27], but the study was nonrandomized and did not meet RIGOR [28] and sTaIR criteria.
Results: High amounts of reteplase were expressed as inclusion bodies in all three strains.
Morrow and his colleagues revealed that prehospital administration of reteplase is a feasible approach to accelerating reperfusion in patients with STEMI.
The researchers recommend other newly developed thrombolytic agents, such as reteplase, have higher clearance rates compared to alteplase (Baskin et al., 2012).
Actavis is the holder of the rights to the Reteplase production process and the distribution of Rapilysin in Europe and worldwide excluding the US and Canada.
The clotted samples were then treated with alteplase, urokinase, streptokinase, tenectoplase, or reteplase. These samples, as well as the normal control (sodium heparinized sample) and the clotted control (untreated clotted sample), were concurrently processed.
Drugs commonly used for DVT thrombolysis are tissue plasminogen activator, urokinase, tenecteplase, and reteplase.
Other thrombolytic enzymes being used for life-threatening indications, such as myocardial infarction and thrombotic stroke, were the transplasminogen activator (tPA), alteplase, and its genetically modified imitator, recombinant plasminogen activator, (rPA) reteplase. These were considered to be much safer immunogenically than streptokinase because tPA is a naturally occurring human protein and so, therefore, this safety is conferred to rPA.
Alteplase (Activase), reteplase (Retavase), and tenecteplase (TNKase), produced with recombinant DNA technology are not teratogenic in experimental animals and are all rated C.
They were first given two doses of reteplase, a drug that breaks up blood clots, and a loading dose and infusion of abciximab, which prevents platelets from clumping to form new clots.
Kringle 2 domain plus the first three amino acids of t-PA has been named reteplase which is available as a thrombolytic agent in the market (7).